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Expression of neutrophil gelatinase-associated
lipocalin in colorectal neoplastic progression: a
marker of malignant potential?
M H McLean*,1, A J Thomson1, G I Murray2, N Fyfe2, G L Hold1 and E M El-Omar1
1Gastrointestinal Research Group, Division of Applied Medicine, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK
and 2Department of Pathology, School of Medicine and Dentistry, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK
Background: Neutrophil gelatinase-associated lipocalin (NGAL) has a diverse functional repertoire, involved in the innate immune
response as well as cell growth and differentiation. Expression has been linked to malignant disease development and
progression.
Methods: Neutrophil gelatinase-associated lipocalin expression was assessed immunohistochemically in 98 colorectal neoplastic
lesions (52 cancer polyps (CaPs) and 46 sporadic adenoma/adjacent normal mucosa paired specimens) to investigate association
with adenoma progression and early colorectal carcinogenesis.
Results:Within CaPs, all adenomatous and carcinomatous epithelium expressed NGAL, with 92% (43 out of 47) and 58% (19 out of
33) epithelial positivity, respectively, as well as positive stromal cell expression. This was significantly increased compared with
normal mucosal epithelium (P¼ 0.0001). Neutrophil gelatinase-associated lipocalin positivity was also identified in sporadic low-
grade adenomas, in both the epithelial and stromal compartments as compared with adjacent normal mucosa (P¼ 0.0001 and
0.0002), and this increased along with adenoma size 41 cm (P¼ 0.03).
Conclusion: Neutrophil gelatinase-associated lipocalin is expressed by the majority of human neoplastic colorectal lesions. This
phenotypic switch occurs at an early stage in neoplastic progression with clear differential expression between normal mucosa
and adenomatous polyps, rather than further downstream in disease progression at the adenoma–carcinoma transformation.
Thus, NGAL expression is not a useful biomarker for determining disease progression from adenomatous to malignant colorectal
neoplasia.
Neutrophil gelatinase-associated lipocalin (NGAL), also known as
lipocalin-2 (LCN-2), is a member of a large lipoprotein superfamily
with over 50 members involved in transmembrane transportation
of small hydrophilic molecules (Bratt, 2000). Specifically, NGAL
promotes the cellular internalisation of siderophores, and this
underpins its role in the innate immune response; it mediates anti-
bacterial action by depleting an essential microbial growth factor,
iron particles, from the surrounding microenvironment. Interest in
NGAL has grown over the last few decades, and it is now clear that
this protein is linked to a spectrum of functions such as cell growth
and differentiation, is systemically released as a pro-inflammatory
signal and as such acts as a biomarker denoting risk and severity in
a number of inflammatory conditions such as acute kidney
injury, and can also be expressed from many cell types as a stress
response. The biology of NGAL in health and disease has been
elegantly reviewed recently by Chakraborty et al (2012). There is
now a growing body of evidence revealing its potential role in
development and progression of malignant disease, and indeed,
increased NGAL expression is linked to cancer in a diverse
array of body sites, such as breast, urinary tract, gynaecological,
thyroid and gastric malignancies (Bolignano et al, 2010;
Chakraborty et al, 2012).
Colorectal cancer is the second cause of cancer death in the
Western world and accounts for significant morbidity and
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mortality (Haggar and Boushey, 2009). The framework of sporadic
colorectal cancer is the adenoma–carcinoma sequence, describing
the change from histologically normal cells to pre-malignant
adenomatous epithelium exhibiting increasing degrees of cell
dysplasia to overt invasive malignant disease (Fearon and
Vogelstein, 1990; Leslie et al, 2002). The pre-malignant phenotype,
colorectal adenomatous polyps, exerts characteristics that denote
high-malignant potential, such as increasing size, increasing degree
of cell dysplasia and greater villous content (O’Brian et al, 1990;
Colucci et al, 2003; Giuliani et al, 2006). These features are central
to the current guidelines on patient management and specifically
interval of surveillance colonoscopy (Cairns et al, 2010). As the
demand for colonoscopy increases, including those participating in
the colorectal screening program, the identification of additional
characteristics of high-malignant potential, such as the expression
of a novel protein biomarker, may assist in risk stratification and
judicious use of endoscopic resource.
There are a few reports linking NGAL expression to colorectal
malignancy (Sun et al, 2011; Barresi et al, 2010, 2011). The most
extensive of these from Sun et al (2011) assessed the expression of
NGAL in a large number of tissue specimens from each stage of the
adenoma–carcinoma sequence, and reported that this was indeed a
marker of neoplastic progression. With specific reference to overt
colorectal cancer, NGAL was significantly linked to increasing
stage of disease, tumour recurrence and overall poorer prognosis.
In addition, there have been reports of NGAL expression in early
colorectal tumours, TNM stage 1, with a correlation to later
survival (Barresi et al, 2010, 2011). With regard to neoplastic
progression along the adenoma–carcinoma sequence, ‘cancer
polyps’ (CaPs) offer an ideal and unique opportunity to investigate
biological events surrounding the earliest point of carcinogenesis.
These lesions by definition include adenomatous background
histology with supervening carcinomatous change, evident by
stromal reaction to invasive disease. Often these lesions also
include histologically normal mucosa at the base, offering the
opportunity to assess expression of a protein marker with each
stage of disease development along the adenoma–carcinoma
sequence, within a single lesion.
The aim of this study was to assess the expression of NGAL in
the progression of colorectal neoplasia, first in a cohort of CaPs,
then in a separate cohort of sporadic colorectal adenomas
compared with adjacent normal colonic mucosa, in order to
identify the point in the adenoma–carcinoma sequence where
NGAL expression becomes prominent and hence assess whether
this could be a biomarker of high-malignant potential in pre-
malignant colorectal polyps.
MATERIALS AND METHODS
Tissue specimens. Neutrophil gelatinase-associated lipocalin
expression was assessed in 98 colorectal neoplastic lesions in total.
The initial cohort included 52 archival paraffin-embedded CaPs
from 52 patients, identified from the pathology department
diagnostic database, Aberdeen Royal Infirmary. All specimens
were reviewed for confirmed histological evidence of normal
colonic mucosa, adenomatous epithelium and an area of super-
vening adenocarcinoma by an expert gastrointestinal pathologist
(GIM). The study was then expanded to include a further 46
sporadic colorectal adenomas and 26 adjacent normal colonic
mucosal samples from 30 patients, collected from the Grampian
colorectal cancer screening program, Aberdeen Royal Infirmary
(McLean et al, 2011). Again, histological diagnosis was confirmed
by an expert GIM. None of these patients had previously
documented colorectal polyps, colorectal malignancy or a history
of inflammatory bowel disease. In addition, there was no known
heritable genetic abnormality documented, specifically none were
noted to belong to a family with Familial Adenomatous Polyposis
or Hereditary Non-polyposis colorectal cancer syndromes. Thus,
this second sample cohort represents sporadic colorectal adenomas
arising in a screened population.
Sections of 4mm were cut and placed onto 3-aminopropyl-
triethoxysilane-coated slides for subsequent immunohistochemical
analysis. The macroscopic size of each polyp was measured
formally as part of the pathological analysis post fixation and
before embedding. This recorded size was used for all polyp
specimens and therefore provided a consistent and precise
measurement of size for all polyps included within this study.
Ethical approval was obtained from Grampian Ethics
Committee.
Neutrophil gelatinase-associated lipocalin immunohistochemistry.
Neutrophil gelatinase-associated lipocalin expression was determined
immunohistochemically with polyclonal rabbit anti-human LCN-2
antibody (Sigma Aldrich, Dorset, UK: HPA002695; validated by
Human Protein Atlas; www.proteinatlas.org) at a dilution of 1 : 800.
Slides were dewaxed, rehydrated and subjected to antigen retrieval by
microwaving for 20min in 10mM citrate buffer, pH 6.0. Tissue
was stained using the Envisionþ peroxidase-linked biotin-free
system on the DakoCytomation (Cambridgeshire, UK) Techmate
Autostainer (Duncan et al, 2008; McLean et al, 2008, 2011). A 60-
min incubation with the primary antibody was incorporated within
the staining protocol, and colour developed with diaminobenzidine.
Sections were counterstained with haematoxylin. Tonsil was used as
a positive control.
Evaluation of immunostaining. All stained sections were assessed
microscopically by two observers (MHM and AJT) independently
and noted to be positive or negative for NGAL expression.
Localisation of positive immunoreactivity to either stromal cells,
epithelial cells or both was documented at  20 magnification with
the whole of the specimen scored over multiple HPFs. Within the
CaPs, this was performed for each histological compartment, i.e.,
normal mucosa, adenomatous epithelium and carcinomatous
epithelium. The end score for each tissue type for both proportion
of stained epithelial cells and intensity of staining was an average of
those obtained from the total tissue assessment. If there was
disagreement on staining pattern, the two observers assessed the
case with a third reviewer (GIM) jointly, and any remaining issues
were resolved by discussion.
The proportion of positive epithelial cell staining and intensity
of epithelial cell staining were scored on a modified scaled system.
For proportion of positive epithelial cells, the scale was as follows:
1p50% of total cell population, and 2X50% of total cell
population. For positive immunoreactivity intensity, 1¼weak/
moderate and 2¼ strong.
Statistical analysis. The association of NGAL expression with
histological cell type and adenoma size was evaluated using the
w2-test with Fisher’s correction performed on a Web-based
statistical w2 calculator (GraphPad.com). Results were deemed
statistically significant if Pp0.05.
RESULTS
Characteristics of colonic neoplastic lesions. The characteristics
(lesion size, colonic site of origin, adenomatous histology type and
degree of dysplasia) of the 98 colorectal neoplastic lesions assessed
for NGAL expression are presented in Table 1. Not all specimens
were taken forward to analysis. On examination of the stained CaP
sections, 1 was fragmented, 4 specimens contained carcinomatous
epithelium in entirety with no adenomatous component and 14 did
not contain carcinomatous epithelium. These were excluded from
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the analysis and therefore the final number of samples included in
the analysis was 47 normal epithelial, 47 adenomatous epithelial
and 33 carcinomatous epithelial compartments.
Expression of NGAL in CaP. There was a statistically significant
increase in total NGAL expression in compartments displaying
colorectal neoplasia compared with normal mucosa (Figure 1;
Table 2). All (100%) of the adenoma- and carcinomatous-defined
compartments in CaP lesions showed NGAL immunopositivity
compared with only 4% (2 out of 47) of normal mucosa
(P¼ 0.0001). Considering the localisation of this immunoreactivity
(Table 3), the two positive normal mucosal specimens exhibited
stromal cell expression with no epithelial cell positivity identified in
this tissue type. In contrast, 43 of the 47 (92%) and 19 of the 33
(58%) adenomatous and carcinomatous epithelium compartments,
respectively, expressed NGAL, a significant increase compared
with normal mucosa (normal vs adenoma, w¼ 75.6, P¼ 0.0001;
normal vs carcinoma, w¼ 32.4, P¼ 0.0001). Notably, there was
significantly less epithelial expression in carcinomatous epithelium
compared with adenomatous epithelium in these CaP lesions
(w¼ 10.9, P¼ 0.001). Considering this epithelial expression, there
was no difference in the intensity or proportion of positive
epithelial cells seen between the adenomatous and carcinomatous
epithelium (Figure 2). The majority of both the adenomatous and
carcinomatous compartments expressed stromal cell positivity: 46
out of 47(98%) and 33 out of 33(100%), respectively. As such, there
was no statistical difference in stromal cell NGAL expression
associated with neoplastic progression from adenoma to carcinoma
(w¼ 0.711, NS). As only 4 out of 47 adenomatous compartments
were negative for epithelial expression of NGAL, the association of
this to differing histology type or degree of dysplasia was unable to
be accessed in this sample group.
Expression of NGAL in normal mucosa–adenoma paired
samples. There was a statistically significant increase in total
NGAL expression in the adenomas compared with adjacent
normal mucosa (67% (31 out of 46) vs 4% (1 out of 26),
respectively, w¼ 26.7, P¼ 0.0001). None of the normal mucosal
Table 1. Characteristics of the 98 colorectal neoplastic lesions assessed
for NGAL expression
Characteristics
CaP identified
from diagnostic
database (n¼52)
Adenomas collected
within paired
polyp–normal
sample set (n¼46)
Colonic site 50 (96%) distal to
splenic flexure
38 (83%) distal to splenic
flexure
Size 1(2%) small o1cm,
51 (98%) large41 cm
16 (35%) smallo1 cm, 30
(65%) large X1 cm
Size range 0.8–3.1 cm 0.3–3 cm
Histological
classification of
adenomatous
epithelium
31 (%) tubular
adenoma, 21 (%)
tubulo-villous
adenomaa
41 (89%) tubular
adenoma, 5 (11%)
tubulo-villous adenoma
Degree of dysplasia of
adenomatous
epithelium
4 (7%) LGD, 12 (27%)
LGD/HGD, 31 (66%)
HGDa
All LGD
Abbreviations: HGD¼high-grade dysplasia; LGD¼ low-grade dysplasia; LGD/HGD¼ LGD
background with foci of HGD.
an¼ 47; four CaP lesions had no adenomatous epithelium seen on stained section and
therefore excluded.
Figure 1. Expression of NGAL in colorectal neoplastic progression.
(A) NGAL epithelial and stromal cell staining in the adenomatous
compartment of a CaP lesion, with no positive staining seen within the
normal mucosa ( 20 magnification). There is a clear demarcation in
staining pattern between these compartments highlighting that
NGAL expression occurs early in the adenoma–carcinoma sequence
with a sharp transition between normal and dysplastic epithelium.
(B) Epithelial and stromal cell NGAL positivity within colonic adenoma
exhibiting low-grade dysplasia ( 40 magnification). (C, D) Epithelial
and stromal cell NGAL positivity within carcinomatous epithelial
compartment of a CaP lesion (40 magnification).
Table 3. Localisation of NGAL positivity (epithelial/stromal) in each
histological compartment of CaP lesions
Normal
colonic
mucosa
n¼47(*,**)
Adenoma
n¼47(*,***)
Carcinoma
n¼33(**,***)
Epithelial cell NGAL positivea 0 (0%) 43 (92%) 19 (58%)
Epithelial cell NGAL negativea 47 (100%) 4 (8%) 14 (42%)
Stromal cell positiveb 2 (4%) 46 (98%) 33 (100%)
Stomal cell negativeb 45 (96%) 1 (2%) 0 (0%)
Abbreviations: CaP¼ cancer polyp; NGAL¼ neutrophil gelatinase-associated lipocalin.
a*Normal vs Adenoma, w¼ 75.6, P¼ 0.0001.
a**Normal vs Carcinoma, w¼ 32.4, P¼ 0.0001.
a***Adenoma vs Carcinoma, w¼ 10.9, P¼ 0.001.
b*Normal vs Adenoma, w¼ 78.7, P¼ 0.0001.
b**Normal vs Carcinoma, w¼ 68.4, P¼ 0.0001.
b***Adenoma vs Carcinoma, not significant.
Table 2. Total NGAL expression in each histological compartment of CaP
lesions (epithelial and stromal)
Normal colonic
mucosa Adenoma Carcinoma
n¼47a,b n¼47a,c n¼33b,c
NGAL positive 2 (4%) 47 (100%) 33 (100%)
NGAL negative 45 (96%) 0 (0%) 0 (0%)
Abbreviation: NGAL¼ neutrophil gelatinase-associated lipocalin.
aNormal vs Adenoma, w¼ 82.5, P¼ 0.0001.
bNormal vs Carcinoma, w¼ 68.4, P¼ 0.0001.
cAdenoma vs Carcinoma, not significant.
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biopsies showed NGAL epithelial positivity. In comparison, almost
half of the adenomatous lesions expressed epithelial NGAL (44%,
20 out of 46), and this difference was statistically significant,
l¼ 13.56, P¼ 0.0002. This epithelial positivity was strong in
intensity in 14 out of 20 adenomas, and in terms of proportion of
positive staining, the majority exhibited positivity in less than half
of the tissue area (13 out of 20). The one normal biopsy that was
positive for NGAL staining showed stromal compartment
immunoreactivity. In the adenoma group, 25 of the 46 (54%)
lesions showed NGAL stromal positivity (normal vs adenoma,
l¼ 16.24, P¼ 0.0001).
NGAL expression in relation to adenoma size. Of the 46
adenoma lesions assessed, 30 were large at X1cm in size and the
remainder (n¼ 16) small at o1cm in size. Table 4 shows NGAL
expression in relation to size. NGAL expression was greater in the
larger adenoma group, and this reached statistical significance
(w¼ 4.69, P¼ 0.03).
DISCUSSION
In this paper, we report that NGAL is expressed by the majority of
human neoplastic colorectal lesions, within both the epithelial and
stromal cell compartments. This phenotypic switch occurs at a very
early stage in neoplastic progression with a clear differential
expression occurring between normal mucosa and adenomatous
polyps, rather than further downstream in disease progression at
the adenoma–carcinoma transformation. This was seen in two
separate and differing cohorts of colorectal neoplastic tissue
specimens representing each side of the neoplastic spectrum,
independent on whether the adenomatous epithelium was within a
low-risk low-grade dysplastic lesion or part of a polyp already
harbouring a malignant focus. Not all adenomas proceed to
malignancy, and it is estimated thato5% of polyps will follow this
fate. It is unclear why this is the case. Our aim was to investigate
if expression of NGAL could be used as a protein biomarker
of high-malignant potential and hence aid determination of
colonoscopic surveillance interval in patients found to have
adenomas on index colonoscopy. However, it is clear from our
data that expression of NGAL per se cannot contribute to
determining the malignant potential of such lesions and aid
clinical decision making in this way.
Sun et al (2011) previously assessed NGAL expression in a large
cohort of colorectal cancers and found a correlation with tumour
progression and patient outcome in a Chinese population. In
keeping with our data, NGAL was largely absent from normal
colonic mucosa. In addition, they assessed expression in over 100
adenomas and reported epithelial positivity in 40% of their low-
grade adenoma cohort, and this increased to 85% within high-
grade dysplastic epithelium. This is in keeping with our current
data that shows epithelial NGAL expression in 92% of mainly
high-grade dysplastic compartments of CaPs, and 67% of our low-
risk low-grade adenomas obtained from colonoscopy as part of the
UK colorectal cancer screening program. In addition, we show that
NGAL expression is linked to polyp size, another physical
characteristic used to assess malignant potential.
It is not a surprise that stromal expression of NGAL is increased
in adenomatous lesions. Neutrophils are the recognised primary
inflammatory cell source of this protein, released into the
surrounding environment as a defence mechanism as part of
innate immunity. Our previous work revealed that the adenoma-
tous microenvironment contains an increased immune cell
infiltrate compared with the adjacent macroscopically normal
mucosa (McLean et al, 2011), rich in neutrophil and macrophage
cells and thus is in keeping with the current data. Similarly, Luley
et al (2011) found increased levels of another granulocyte-derived
protein calprotectin in adenomas compared with adjacent normal
mucosa, and this correlated strongly with an increased neutrophil
infiltrate seen in colonic polyps, comparable in magnitude to
that in overt colorectal cancer. Similarly, myeloperoxidase
positivity, used as an immunohistochemical marker of granulocyte
infiltration, was increased in correlation with neoplastic progres-
sion, with increasing inflammatory cell infiltrates identified within
aberrant crypt foci to adenomas to overt invasive malignancy
(Roncucci et al, 2008).
The key questions revolve around the expression of NGAL in
the epithelial compartment of the adenomatous lesions – what is its
role in this setting, what triggers it’s expression and what influence
does it have on disease progression? Devireddy et al (2005)
reported that iron-rich ligand binding to the LCN-2 receptor
increases intra-cellular iron and inhibits apoptosis, conferring a
growth advantage. Jung et al (2012) showed macrophage-derived
NGAL stimulates growth of in vitro breast cancer cell lines. In
addition, expression signature of NGAL in breast cancer tissue
follows disease progression, by expression of mesenchymal
markers and loss of E-cadherin expression, promoting invasive
disease (Yang et al, 2009). Indeed, in a colorectal cancer cell line,
NGAL overexpression was linked to loss of cell-to-cell adhesion
and increased invasion (Hu et al, 2009). Similarly, an in vivomouse
model of xenographic colon cancer linked increased expression of
NGAL to increased tumour growth and metastatic disease (Sun
et al, 2011). Another mechanism that may promote this phenotype
is the formation of NGAL/MMP-9 complexes, protecting the latter
proteolytic enzyme from degradation, with negative correlation to
tissue degradation and invasion (Bolignano et al, 2010). However,
Barresi et al (2011) reported expression of NGAL as a negative
prognostic marker in early colorectal carcinoma that was not
dependent on concurrent expression of MMP-9.
It is clear that NGAL can potentially promote tumorigenesis
via several different mechanisms and this can differ in
different tissue types (reviewed in Bolignano et al, 2010 and
37 37
63 63
51
4749
53
Adenoma Carcinoma
I1 (weak/moderate) I2 (strong) P2 (>50%)
Figure 2. Proportion of positive epithelial cells and intensity of
epithelial cell staining did not differ between adenomatous and
carcinomatous epithelium within CaP lesions. Numerical values
represent % of total specimens/histological compartment. I¼ intensity;
P¼proportion of total tissue section.
Table 4. Total NGAL expression related to adenoma size
Small adenoma
(o1cm), n¼16
Large adenoma
(X1 cm), n¼30
NGAL positive 7 24
NGAL negative 9 6
Abbreviation: NGAL¼neutrophil gelatinase-associated lipocalin. w¼ 4.69, P¼ 0.03.
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Chakraborty et al, 2012). This is supported by the finding that
expression of NGAL during embryogenesis and development is
tissue specific. In the gastrointestinal tract, NGAL is strongly
expressed at an embryonic stage to 16 weeks of fetal development,
and then vanishes (Zhang et al, 2012). Our data suggest that this
expression then reappears in dysplastic colonic epithelia. NGAL
has previously been reported in additional pre-malignant pathol-
ogies, such as endometrial (Miyamoto et al, 2011) and pancreatic
(Moniaux et al, 2008) sites.
Overall, this study reveals that expression of NGAL in neoplastic
colonic epithelium occurs very early in the adenoma–carcinoma
sequence with the phenotypic switch seen at the normal to
adenoma transition. Consequently, the majority of adenomas
express NGAL, particularly with increasing adenoma size, and this
may be important in the transition to malignancy. We aimed to
assess whether NGAL could be used as a protein biomarker of
malignant potential, and given the extensive expression rate in
adenomas, this was not the case. However, the nature and the
consequences of NGAL expression, particularly in the epithelial
compartment, are of interest in understanding early colorectal
carcinogenesis and warrant further investigation.
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